Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marksans PharmaBOM:524404 -0.23%83 Days Inventory is 227.11 as of Mar. 2026, which is 27% above its 10-year median of 178.66. GuruFocus rates BOM:524404 with a GF Score™ of 83/100 and a GF Value™ of ₹230.82 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 923 Drug Manufacturers companies, Marksans Pharma ranks worse than 78.22% on this metric.
The historical rank and industry rank for Marksans Pharma's Days Inventory or its related term are showing as below:
BOM:524404'
s Days Inventory Range Over the Past 10 Years
Min: 133.97 Med: 178.66 Max: 264.14
Current: 264.14
During the past 13 years, Marksans Pharma's highest Days Inventory was 264.14. The lowest was 133.97. And the median was 178.66.
BOM:524404's Days Inventory is ranked worse than 78.22% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.87
vs BOM:524404: 264.14
Marksans Pharma's Days Inventory
declined
from Mar. 2025 (237.23) to Mar. 2026 (227.11).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Marksans Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.40.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Marksans Pharma's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.14.
Marksans Pharma (BOM:524404) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Marksans Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Marksans Pharma's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Marksans Pharma Days Inventory Related Terms
Marksans Pharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Marksans Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524404 vs LLY, JNJ, ABBV: Days Inventory Comparison
For the Drug Manufacturers - General subindustry, Marksans Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marksans Pharma Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Marksans Pharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marksans Pharma (BOM:524404) has a Days Inventory of 227.11 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Marksans Pharma and its competitors. This is 27% above median its historical median of 178.66. Over the past decade, Marksans Pharma's Days Inventory has ranged from 133.97 to 264.14. According to the industry distribution chart, Marksans Pharma ranks #722 out of 923 companies in the Drug Manufacturers industry, placing it in the top 78.2%.
Is Marksans Pharma's Days Inventory too high?
Marksans Pharma's current Days Inventory of 227.11 is 27% above median its 10-year median of 178.66. Over the past 10 years, this metric has ranged from a low of 133.97 to a high of 264.14. The Drug Manufacturers industry median Days Inventory is 164.87. Marksans Pharma's value of 227.11 is 37.8% above this industry median. Based on the distribution chart, Marksans Pharma ranks #722 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Marksans Pharma has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Marksans Pharma's Days Inventory compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Marksans Pharma ranks #722 out of 923 companies for Days Inventory. This places Marksans Pharma in the lower half of its industry. The industry median Days Inventory is 164.87. Marksans Pharma's value of 227.11 is 37.8% above this benchmark. Historically, Marksans Pharma's own Days Inventory has ranged from 133.97 to 264.14 over the past decade. While the company's 10-year median is 178.66 vs. the industry median of 164.87, Marksans Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.87, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marksans Pharma's current Days Inventory of 227.11 is 37.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Marksans Pharma and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marksans Pharma's current Days Inventory is 227.11, which is 27% above median its own 10-year median of 178.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marksans Pharma stock overvalued right now?
Based on GuruFocus' analysis, Marksans Pharma (BOM:524404) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹230.82, compared to a current price of ₹258.00 — trading 11.8% above its estimated fair value. The current Days Inventory is 227.11, which is 27% above median its 10-year median of 178.66 and 37.8% above the Drug Manufacturers industry median of 164.87. Marksans Pharma's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Marksans Pharma (BOM:524404), the current Days Inventory is 227.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marksans Pharma (BOM:524404) Overvalued in 2026?
Based on GuruFocus' analysis, Marksans Pharma stock appears to be overvalued.
The current stock price of ₹258.00 is trading 11.8% above its estimated GF Value™ of ₹230.82.
GuruFocus considers Marksans Pharma to be Modestly Overvalued.
Key valuation signals for BOM:524404:
Days Inventory: 227.11 (27% above median its 10-year median of 178.66)
GF Value™: ₹230.82 vs. price of ₹258.00 (11.8% above fair value)
Industry Position: 37.8% above the Drug Manufacturers median (#722 of 923)
No single metric tells the full story. See the BOM:524404 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
83GF Score
Get the complete analysis for BOM:524404
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524404 has been successfully added to your 
